	US 12,448,438 B2
	Anti-IL31 antibodies for veterinary use
Shyr Jiann Li, Burlingame, CA (US); Lam Nguyen, Burlingame, CA (US); and Hangjun Zhan, Burlingame, CA (US)
Assigned to Elanco US Inc., Greenfield, IN (US)
Filed by Elanco US Inc., Greenfield, IN (US)
Filed on May 3, 2023, as Appl. No. 18/311,777.
Application 18/311,777 is a continuation of application No. 16/488,045, granted, now 11,673,946, previously published as PCT/US2018/017623, filed on Feb. 9, 2018.
Claims priority of provisional application 62/463,543, filed on Feb. 24, 2017.
Prior Publication US 2024/0101660 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 2039/552 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

29 Claims

1. A pharmaceutical composition comprising an anti-IL31 antibody and a pharmaceutically acceptable carrier, wherein the antibody comprises:

a) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1,

(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2,

(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and

b) (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 8,

(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 9,

(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10.